To address this problem, Trace has been working on a type of drug known as an antisense therapy, which the company designed ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that it will present new preclinical ...

Lung cancer, specifically Non-Small Cell Lung Cancer (NSCLC)-the most common subtype of cancer contracted by patients who do not smoke, is a leading ...

AiCuris Anti-infective Cures AG today announced the initiation of its Phase 1, first-in-human trial of AIC468, a novel antisense oligonucleotide. AIC468 is an antiviral agent which aims to treat BK ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

The antisense nucleotide for Timothy syndrome was designed to ... Diagnostic capabilities can potentially be extended to ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing ...